What's Happening?
A study by Rutgers University, published in Criminology, suggests that GLP-1 medications like Ozempic and Wegovy may reduce the risk of violent behavior. The research found that the link between impulsivity and violence was 62% weaker among current GLP-1 users
compared to former users. Similarly, the connection between alcohol use and violence was 52% weaker among current users. The study analyzed data from a 2025 survey of 7,521 U.S. adults, focusing on 821 individuals who had used GLP-1 medications. The findings suggest that these drugs may work like cognitive behavioral therapy, weakening the path from impulse to action.
Why It's Important?
The potential of GLP-1 medications to reduce violent behavior has significant implications for public safety and health. If these drugs can effectively decrease aggression, they could be used as a tool for managing violent behavior in certain populations. This could lead to broader applications of GLP-1 drugs beyond their current use, offering new strategies for addressing societal issues related to violence and crime. Understanding the behavioral effects of these medications could also inform public health policies and interventions.
What's Next?
Further research is needed to establish a causal relationship between GLP-1 medication use and reduced violence. Longitudinal studies could provide more insights into the long-term effects of these drugs on behavior. As GLP-1 medications become more widespread, it will be important to monitor their impact on public safety and mental health. Researchers may also explore the potential of these drugs in treating other conditions related to impulsivity and aggression.
